Corporate Banner
Satellite Banner
Biomolecular Screening
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

3D cell Culture Firm Reinnervate and Specialist Oncology CRO Oncotest GmbH Enter Collaboration Agreement

Published: Monday, January 07, 2013
Last Updated: Monday, January 07, 2013
Bookmark and Share
Oncotest to offer enhanced pre-clinical oncology and cancer research screening services incorporating Alvetex®Scaffold 3D cell culture technology.

Under the terms of the partnership, Oncotest will offer its clients automated assays based on Alvetex®Scaffold technology, complementing their well known 3D Tumour Clonogenic Assay technology.

Prof. Stefan Przyborski, founder and CSO of Reinnervate described the benefits of the 96 well plates for cancer cell cytotoxicity testing; ‘The Alvetex®Scaffold 96 well plate allows scientists to grow tumour cells in 3D, better mimicking the way these cells grow in vivo. It is very easy to start using 3D cell culture with Alvetex® technology. You simply seed the cells, add your existing media and place in your standard incubator. There is no struggling with new and sometimes cumbersome protocols required with other 3D technologies such as collagen gels or hanging drops’. He then went on to say; ‘We have shown that the Alvetex®Scaffold 96 well plates work seamlessly with automated platforms and standard cell health assays such as MTT, XTT, Cell Titer-Glo® and many others.’

Prof. Heiner Fiebig, founder and CEO of Oncotest said, ‘We are very pleased to be able to offer cancer cell cytotoxicity assays using Alvetex®Scaffold 96 well plates to our clients. We have looked at several different technologies and found Alvetex®Scaffold to be the simplest and most reliable solution. We particularly value the ease of use, ability to automate the entire workflow and the ability to isolate protein and RNA from the treated cells to study drug effects post-treatment. The combination of Alvetex®Scaffold, state-of-the-art co-culture techniques and our automated 96 well 3D assay technology will also potentially allow the study of effects of anti-cancer molecules which target parts of the tumour microenvironment. This powerful ex vivo culture system will be a very exciting new tool for our clients. The assay platform can be used with both Oncotest’s patient-derived tumour xenografts (as an ex vivo assay) and for established tumour cell lines (as an in vitro assay)’.

Oncotest will begin offering services immediately to existing clients, and will offer a new introductory screening service for companies new to 3D cell culture who want to try out 3D culture based oncology services.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,200+ scientific posters on ePosters
  • More than 4,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Alvetex® Voted One of Most Technologically Significant New Research Products By R&D Magazine
Alvetex® enables genuine 3D cell growth to be performed routinely and cost effectively in cell biology laboratories.
Monday, June 27, 2011
Alvetex® Named in the “Top Ten Life Science Innovations of 2010” by The Scientist Magazine
Reinnervate’s 3D cell culture technology selected as one the ten most exciting new tools to hit the life sciences market this year.
Monday, December 06, 2010
Reinnervate Partners with LGC for Global Distribution of Alvetex®
Additional collaboration to develop 3d cell cultures for applications in drug discovery and development.
Tuesday, November 30, 2010
Cell Growth Technology Promises More Successful Drug Development
The technology allows cells to be grown in a more realistic three-dimensional form compared to the traditional flat surface of a Petri dish.
Friday, September 21, 2007
Scientific News
New Cancer Drug Target in Dual-Function Protein
Scientists at The Scripps Research Institute (TSRI) have identified a protein that launches cancer growth and appears to contribute to higher mortality in breast cancer patients.
Penn State, TB Alliance, and GSK Partner To Discover New Treatments For TB
A new collaboration between TB Alliance, GSK, and scientists in the Eberly College of Science seeks to find new small molecules that can be used to create antibiotics in the fight against tuberculosis (TB).
Molecular Map Provides Clues To Zinc-Related Diseases
Mapping the molecular structure where medicine goes to work is a crucial step toward drug discovery against deadly diseases.
Platelets are the Pathfinders for Leukocyte Extravasation During Inflammation
Findings from the study could help in the prevention and treatment of inflammatory pathologies.
Genetic Research Can Significantly Improve Drug Development
With drug development costs topping $1.2bn (£850 million) to get a single treatment to the point it can be sold and used in the clinic, could genetic analysis save hundreds of millions of dollars?
New Method Opens Door to Development of Many New Medicines
Findings from TSRI reveal human proteins are better drug targets than previously thought.
Diagnosing Systemic Infections Quickly, Reliably
Team develop rapid and specific diagnostic assay that could help physicians decide within an hour whether a patient has a systemic infection and should be hospitalized for aggressive intervention therapy.
What Makes a Good Scientist?
It’s the journey, not just the destination that counts as a scientist when conducting research.
Blood Test That Detects Early Alzheimer’s Disease
A research team, led by Dr. Robert Nagele from Rowan University School of Osteopathic Medicine and Durin Technologies, Inc., has announced the development of a blood test that leverages the body’s immune response system to detect an early stage of Alzheimer’s disease – referred to as the mild cognitive impairment (MCI) stage – with unparalleled accuracy.
A New Approach to Chemical Synthesis
Communesins, originally found in fungus, could hold potential as cancer drugs.
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,200+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!